[go: up one dir, main page]

UA87009C2 - Композиции, которые содержат гибридные белки-аналоги glp-1 - Google Patents

Композиции, которые содержат гибридные белки-аналоги glp-1

Info

Publication number
UA87009C2
UA87009C2 UAA200706803A UAA200706803A UA87009C2 UA 87009 C2 UA87009 C2 UA 87009C2 UA A200706803 A UAA200706803 A UA A200706803A UA A200706803 A UAA200706803 A UA A200706803A UA 87009 C2 UA87009 C2 UA 87009C2
Authority
UA
Ukraine
Prior art keywords
glp
fusion protein
fusion
formulations
protein formulations
Prior art date
Application number
UAA200706803A
Other languages
English (en)
Ukrainian (uk)
Inventor
Вольфганг Глезнер
мл. Милликан Рон Ли
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of UA87009C2 publication Critical patent/UA87009C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к стойкой растворимой композиции, которая содержит гибридный белок GLP-1-Fc при рН в пределах от приблизительно рН 6 до приблизительно рН 8,5. Аналоги являются слитыми с конкретными производными IgG4-Fc. Эти композиции обеспечивают неожидаемую и значительно высшую химическую стойкость в случае сравнения с гибридными белками GLP-1-Fc при рН за пределами описанных диапазонов. Композиции, которые содержат гибридный белок GLP-1-Fc, полезны при лечении диабета, ожирения, синдрома разраженной толстой кишки и других состояний, благотворным для которых было бы снижение уровней глюкозы в плазме, угнетение подвижной функции желудка и/или перистальтики кишечника и угнетение опорожнения желудка и/или кишечника или угнетение потребления пищи.
UAA200706803A 2004-12-22 2005-12-15 Композиции, которые содержат гибридные белки-аналоги glp-1 UA87009C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64169004P 2004-12-22 2004-12-22

Publications (1)

Publication Number Publication Date
UA87009C2 true UA87009C2 (ru) 2009-06-10

Family

ID=36123207

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200706803A UA87009C2 (ru) 2004-12-22 2005-12-15 Композиции, которые содержат гибридные белки-аналоги glp-1

Country Status (22)

Country Link
US (1) US20090232807A1 (ru)
EP (2) EP1831252B1 (ru)
JP (1) JP2008525452A (ru)
KR (1) KR100879662B1 (ru)
CN (1) CN101044162B (ru)
AT (1) ATE435235T1 (ru)
AU (1) AU2005319432A1 (ru)
BR (1) BRPI0519393A2 (ru)
CA (1) CA2589647A1 (ru)
CY (1) CY1109269T1 (ru)
DE (1) DE602005015257D1 (ru)
DK (1) DK1831252T3 (ru)
EA (1) EA011166B1 (ru)
ES (1) ES2326906T3 (ru)
IL (1) IL183285A0 (ru)
MX (1) MX2007007565A (ru)
NO (1) NO20073372L (ru)
PL (1) PL1831252T3 (ru)
PT (1) PT1831252E (ru)
SI (1) SI1831252T1 (ru)
UA (1) UA87009C2 (ru)
WO (1) WO2006068910A1 (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
CN101730523A (zh) * 2007-07-10 2010-06-09 伊莱利利公司 GLP-1-Fc融合蛋白质制剂
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
US20120231022A1 (en) 2009-05-28 2012-09-13 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
CN103124739B (zh) * 2010-05-17 2015-11-25 贝达药业股份有限公司 一种新胰高血糖素样肽类似物、组合物及其用途
CN102533655A (zh) * 2010-12-21 2012-07-04 青岛黄海制药有限责任公司 高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法
JP2014504588A (ja) 2010-12-22 2014-02-24 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 膵島細胞移植のためのｇｌｐ−１受容体アゴニスト
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SI2934568T1 (en) 2012-12-21 2018-03-30 Sanofi Dual GLP1 / GIP or trigonal agonists GLP1 / GIP / glucagon
CN104173275A (zh) * 2013-05-21 2014-12-03 深圳翰宇药业股份有限公司 度拉鲁肽注射剂及其制备方法
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
UA124182C2 (uk) * 2014-03-31 2021-08-04 Ханмі Фарм. Ко., Лтд. Спосіб покращення розчинності фізіологічно активного білка або пептиду
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104327187B (zh) * 2014-10-11 2018-06-08 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
US20160137712A1 (en) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Fusion Proteins With Dual Receptor Agonist Activities
CN105854000A (zh) * 2015-02-11 2016-08-17 杭州鸿运华宁生物医药工程有限公司 一种药用glp-1r抗体融合蛋白的稳定溶液制剂
US10993993B2 (en) * 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
UA127495C2 (uk) 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
JOP20190177A1 (ar) * 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
MA49460A (fr) 2017-06-20 2020-04-29 Amgen Inc Méthode de traitement ou de réduction de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1
AU2018288852B2 (en) 2017-06-21 2025-02-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins
EP3668536A4 (en) 2017-08-15 2021-05-26 Kindred Biosciences, Inc. IGG-FC VARIANTS FOR USE IN VETERINARY MEDICINE
KR20220146656A (ko) 2017-11-21 2022-11-01 일라이 릴리 앤드 캄파니 둘라글루티드를 함유하는 조성물 및 사용 방법
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
JP7728176B2 (ja) 2019-03-15 2025-08-22 イーライ リリー アンド カンパニー 保存製剤
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
US20210187077A1 (en) * 2019-12-23 2021-06-24 Idaho State University GLP-1 Agonist Conjugates for Sustained Glycemic Control
CA3241537A1 (en) * 2021-12-31 2023-07-06 Jiangyu YAN Fusion protein of glp-1 and gdf15 and use thereof
US20240335513A1 (en) * 2022-05-30 2024-10-10 Zealand Pharma A/S Liquid formulations of amylin analogues

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
JP2004528014A (ja) * 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１融合タンパク質
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US7452966B2 (en) * 2003-06-12 2008-11-18 Eli Lilly And Company GLP-1 analog fusion proteins

Also Published As

Publication number Publication date
ATE435235T1 (de) 2009-07-15
JP2008525452A (ja) 2008-07-17
ES2326906T3 (es) 2009-10-21
EA011166B1 (ru) 2009-02-27
DE602005015257D1 (ru) 2009-08-13
US20090232807A1 (en) 2009-09-17
KR20070089187A (ko) 2007-08-30
PT1831252E (pt) 2009-09-17
PL1831252T3 (pl) 2009-11-30
CY1109269T1 (el) 2014-07-02
WO2006068910A1 (en) 2006-06-29
AU2005319432A1 (en) 2006-06-29
CN101044162A (zh) 2007-09-26
EP1831252B1 (en) 2009-07-01
EA200701364A1 (ru) 2007-10-26
IL183285A0 (en) 2007-09-20
HK1107570A1 (en) 2008-04-11
KR100879662B1 (ko) 2009-01-20
CA2589647A1 (en) 2006-06-29
EP1831252A1 (en) 2007-09-12
EP2168982A1 (en) 2010-03-31
DK1831252T3 (da) 2009-10-05
NO20073372L (no) 2007-07-16
CN101044162B (zh) 2010-10-27
BRPI0519393A2 (pt) 2009-01-20
SI1831252T1 (sl) 2009-12-31
MX2007007565A (es) 2007-07-24

Similar Documents

Publication Publication Date Title
UA87009C2 (ru) Композиции, которые содержат гибридные белки-аналоги glp-1
TW200507870A (en) GLP-1 analog fusion proteins
NO20076415L (no) GLP-1 pegylerte forbindelser
UA92451C2 (en) Polyethelene glycol link glp-1 compounds
WO2000074666A3 (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2005012243A3 (en) Substituted indole-o-glucosides
UA86042C2 (en) Substituted indazole-o-glucosides
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
DE60110054D1 (en) Cardioprotektive phosphonate
WO2007014619A8 (en) Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
MX2007007174A (es) Derivados de cicloalquilamina.
WO2006042152A3 (en) Vasoactive intestinal polypeptide pharmaceuticals
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
EP1561472A4 (en) SOLID PREPARATION
WO2002044113A3 (en) Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
WO2007044591A3 (en) Vasoactive intestinal polypeptide pharmaceuticals
DK1465641T3 (da) Lægemidler indeholdende deuterium til behandling af sukkersyge
TNSN05065A1 (en) Use of prebiotics for the treatment and prevention of hyperglycaemic syndromes
WO2003024946A3 (en) Oxamate derivatives containing a variously substituted nitrogen heterocycle